Myriad Genetics Announces Precise MRD Clinical Data
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular…
New Meta-Analysis Demonstrates that Access to the GeneSight
SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular…
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics, Inc. SALT LAKE CITY, Aug. 27, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a…
Opendoor, SmartRent, Myriad Genetics, Reddit, and Unity Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the major indices continued to pull back, with…
Myriad Genetics Appoints Ben Wheeler Chief Financial
SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular…
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
Myriad Genetics, Inc. SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a…
Our Top 5 Analyst Questions
Myriad Genetics reported flat year-over-year sales in Q2, but the market responded positively due to results that surpassed…
Sarepta Says Deaths of Two Elevidys Patients Posted on FDA Database Unrelated to Treatment
Sarepta Therapeutics (NASDAQ: SRPT) said Friday that the deaths of two patients taking its marketed gene therapy Elevidys®…
Myriad Genetics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags – uk.finance.yahoo.com
Myriad Genetics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags uk.finance.yahoo.comMyriad Genetics (MYGN) Q2 Earnings and Revenues Surpass…
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
1 Attributable to UNH discontinuation of coverage (commercial and managed Medicaid) of GeneSight and the divestiture of the…
Myriad Genetics Announces New $200 Million Credit Facility
Myriad Genetics, Inc. SALT LAKE CITY, July 31, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a…
Why Myriad Genetics (MYGN) Shares Are Falling Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 3.8% in the afternoon session after weakness in the…